hERG screening alone may be insufficient to flag potential cardiac liability. Conversely, abandoning promising compounds based on hERG blockade alone may result in failing potentially safe clinical drugs.

Creative Bioarray's CiPA service provides you with a robust cost-effective approach to determine cardiac risk, earlier in your program and with turnaround times that support your lead discovery and optimization pipeline.